Skip to main content

4 Result(s)

within Jean-Michel Karsenti Remove this filter

and

  1. Article

    Open Access

    Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

    Alix Dubois, Nathan Furstoss, Anne Calleja, Marwa Zerhouni, Thomas Cluzeau… in Leukemia (2020)

    Download PDF (171 KB) View Article

  2. Article

    Open Access

    Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up

    In total, 279 patients with hairy-cell leukemia (HCL) were analyzed, with a median follow-up of 10 years. Data were collected up to June 2018. We analyzed responses to treatment, relapses, survival, and the oc...

    Jerome Paillassa, Edouard Cornet, Stephanie Noel, Cecile Tomowiak… in Blood Cancer Journal (2020)

    Download PDF (905 KB) View Article

  3. No Access

    Article

    RETRACTED ARTICLE: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML

    Chaperone-mediated autophagy (CMA) is a highly selective form of autophagy. During CMA, the HSC70 chaperone carries target proteins endowed with a KFERQ-like motif to the lysosomal receptor LAMP2A, which then ...

    Alix Dubois, Nathan Furstoss, Anne Calleja, Marwa Zerhouni, Thomas Cluzeau… in Leukemia (2019)

  4. No Access

    Article

    Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level

    Myelodysplastic syndromes (MDS) are associated with increased bone marrow vascularity and increased levels of various angiogenic factors including Vascular Endothelial Growth Factor (VEGF) which is implicated ...

    Laurence Legros, Bohrane Slama, Jean-Michel Karsenti, Norbert Vey… in Annals of Hematology (2012)